Opaleye Management Inc. 13D and 13G filings for Eton Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-09-12 4:05 pm Purchase | 2024-09-09 | 13G | Eton Pharmaceuticals, Inc. ETON | Opaleye Management Inc. | 2,722,500 10.340% | 197,613 (+7.83%) | Filing |
| 2024-02-09 4:05 pm Purchase | 2023-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON | Opaleye Management Inc. | 2,524,887 9.840% | 354,887 (+16.35%) | Filing |
| 2023-01-20 4:53 pm Sale | 2022-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON | Opaleye Management Inc. | 2,170,000 8.580% | -215,000 (-9.01%) | Filing |
| 2022-01-24 4:05 pm Sale | 2021-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON | Opaleye Management Inc. | 2,385,000 9.690% | -1,307,700 (-35.41%) | Filing |
| 2021-06-17 4:40 pm Purchase | 2020-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON | Opaleye Management Inc. | 3,692,700 15.070% | 52,700 (+1.45%) | Filing |